Novartis aims to broaden use of breast cancer drug

November 17, 2017

Novartis is looking for an expanded combination therapy label for its Kisqali after a trial showed it halts progression of an aggressive kind of breast cancer in younger women for longer than standard drugs.

The Swiss pharma said it plans to approach regulators with results of the MONALEESA-7 phase 3 trial in order to broaden the use of Kisqali (ribociclib).

This could help it steal a march over Pfizer and Eli Lilly, who have rival treatments in the therapy area.